2026 Annual Report & Appendix 4E
Filed with ASX · · 99 pages · English
Summary by 6ix AI
The report indicates a decrease in revenue from ordinary activities and an increase in the loss attributable to the owners of the company compared to the previous year. Despite these challenges, the company reported significant growth in core testing revenue and completed a strategic transition to focus on core testing products.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Microba Life Sciences' latest callMicroba Life Sciences (ASX:MAP) Q4 2025 Earnings Call · Replay · Jul 22, 2025Read the transcript of Microba Life Sciences (ASX:MAP) Q4 2025 Earnings CallMicroba Life Sciences Limited on 6ix
Story so far
Earlier from Microba Life Sciences
- Genetic Signatures and Microba in Merger Discussions
- Q4 FY26 Quarterly Investor Presentation & Webinar
- Investor presentation - path to cashflow breakeven
- Pause in Trading
- Q3 FY26 Quarterly Investor Presentation & Webinar
Later from Microba Life Sciences
- GSS and MAP agree to Commercial Terms for Merger
- Appointment of Interim Chief Executive Officer
- Microba secures $2m placement and increases cost reductions
- Q1 FY27 Quarterly Activities Report & Appendix 4C
- Update on Commercial Terms for Proposed Merger with MAP
Follow Microba Life Sciences into a list and get an email when it puts out news.
Follow Microba Life Sciences